Insights
SPRAVATO® vs. TMS: How to Think About Choosing
Quick answer
SPRAVATO® (esketamine) and TMS are both FDA-backed options for depression that hasn't responded adequately to antidepressants, both are commonly covered by insurance including Medicare, and both are delivered as structured courses in a clinic. The lived experience is where they diverge: TMS is a brief daily appointment with no medication, no altered state, and you drive yourself; SPRAVATO® is a less frequent visit built around a medication that commonly causes temporary dissociation, with a two-hour monitoring window and a ride home required. This clinic offers both — which means this guide has no reason to sell you either one. Here's how the choice actually gets made.
Why this comparison is worth taking seriously
If you've reached the point of comparing these two, you've likely already done the hard part: multiple medication trials without enough relief. Both of these treatments exist for exactly that situation — SPRAVATO® is approved for treatment-resistant depression (and for depressive symptoms in adults with MDD with acute suicidal thoughts or actions), and TMS is FDA-cleared for depression including anxious depression, with additional clearances for OCD and adolescent depression (ages 15–21). From here, the decision is less "which is the real treatment" and more "which structure, experience, and mechanism fit my life and my case."
The experience: about as different as two clinic treatments get
TMS is a roughly 20-minute session in a chair, awake and unsedated, with magnetic pulses tapping at the scalp. There's no drug in your system, no altered state, no recovery time — you drive in, get treated, and drive back to work. The trade-off is frequency: the initial course typically runs five days a week for several weeks, so the demand is calendar-shaped, not experience-shaped.
SPRAVATO® flips that. Visits are less frequent — typically twice weekly during the initial phase, spacing out over time — but each one is longer and involves a medication experience: dissociation, sleepiness, and dizziness are common and expected, every dose is followed by an observation period of about two hours, and you need a ride home with no driving until the next day. The demand is experience-shaped, not calendar-shaped.
Neither structure is objectively easier. A five-day-a-week commute is a real burden for some lives; a recurring altered-state experience plus a ride-home requirement is a real burden for others. Which burden fits your work, family, and temperament is a legitimately personal question — and often the deciding one.
Mechanism, for those who want it
TMS stimulates mood-regulation circuits directly with focused magnetic pulses — a device-based approach with no systemic medication. SPRAVATO® works pharmacologically through the brain's glutamate system, a different mechanism from standard antidepressants, which is part of why it can help where they haven't. Different mechanisms also mean non-response to one doesn't predict non-response to the other — clinically useful, because these treatments can be sequenced.
The practical grid
Insurance: both commonly covered, including Medicare, for treatment-resistant depression with prior authorization — expect benefits verification and paperwork either way.
Driving: TMS yes, every day; SPRAVATO® no — ride required, driving resumes the next day.
Session time: TMS ~20 minutes; SPRAVATO® a multi-hour visit including observation.
Course shape: TMS front-loads (daily, then done); SPRAVATO® starts twice-weekly and tapers, sometimes continuing as maintenance.
Eligibility nuances: ages 15–21 with depression point toward TMS's adolescent clearance; acute suicidal symptoms in adults with MDD are specifically within SPRAVATO®'s approval; screening findings (like seizure-risk factors for TMS or blood-pressure concerns for SPRAVATO®) can tilt the decision — which is what evaluation is for.
How patients actually choose
In practice the decision usually falls out of three honest questions. Can I make a daily appointment work for several weeks? (If no — SPRAVATO®'s lighter calendar wins ground.) How do I feel about a dissociative medication experience versus no drug at all? (Strong feelings here often decide the whole thing.) And what does my psychiatric evaluation say about my specific case? Screening findings, symptom severity, and history sometimes make the choice clearer than any preference grid.
And it's worth knowing the choice isn't final: at a clinic offering both, a patient who doesn't respond adequately to one can move to the other — or discuss medically supervised ketamine or medication changes — without starting over somewhere new. That continuity is the practical argument for choosing a clinic by breadth, not just by which single treatment it sells.
TMS Therapy Centers Colorado provides both TMS and certified SPRAVATO® treatment (plus supervised ketamine therapy, psychiatric evaluation, and medication management) under one roof in Aurora. A free consultation is where your three questions get real answers: 720-500-PTSD — or read deeper on our TMS therapy and SPRAVATO® pages.